SELLAS Life Sciences Group, Inc.

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies or a broad range of cancer indications.

SELLAS’ lead product candidate, galinpepimut-S (GPS), licensed from Memorial Sloan-Kettering Cancer Center (MSKCC), is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The WT1 antigen is one of the most widely expressed cancer antigens and is ranked by the National Cancer Institute (NCI) as the top priority among cancer antigens for immunotherapy. Traditional approaches have not yet been proven to successfully address the WT1 protein, as WT1 is not druggable with small molecules and is intracellular and inaccessible to antibodies.

Click here to download the Sellas Life Sciences Shareholder Update.

News Feed